Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 28% ± 12% | |
oligodendrocyte precursor cell | 9 studies | 31% ± 16% | |
oligodendrocyte | 9 studies | 28% ± 10% | |
glutamatergic neuron | 8 studies | 41% ± 27% | |
microglial cell | 8 studies | 29% ± 10% | |
astrocyte | 8 studies | 28% ± 11% | |
GABAergic neuron | 7 studies | 39% ± 21% | |
neuron | 6 studies | 32% ± 15% | |
interneuron | 6 studies | 38% ± 22% | |
macrophage | 6 studies | 32% ± 8% | |
adipocyte | 6 studies | 22% ± 5% | |
fibroblast | 6 studies | 21% ± 8% | |
epithelial cell | 5 studies | 35% ± 12% | |
B cell | 4 studies | 20% ± 1% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 16% ± 0% | |
myeloid cell | 4 studies | 18% ± 2% | |
lymphocyte | 4 studies | 22% ± 8% | |
endothelial cell of lymphatic vessel | 4 studies | 25% ± 7% | |
smooth muscle cell | 4 studies | 17% ± 1% | |
classical monocyte | 3 studies | 20% ± 3% | |
granule cell | 3 studies | 21% ± 4% | |
ciliated cell | 3 studies | 20% ± 2% | |
basal cell | 3 studies | 29% ± 16% | |
hepatocyte | 3 studies | 34% ± 22% | |
CD8-positive, alpha-beta T cell | 3 studies | 16% ± 1% | |
natural killer cell | 3 studies | 17% ± 1% | |
T cell | 3 studies | 16% ± 1% | |
pericyte | 3 studies | 23% ± 10% | |
type I pneumocyte | 3 studies | 23% ± 6% | |
plasmacytoid dendritic cell | 3 studies | 23% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3396.29 | 1445 / 1445 | 100% | 20.78 | 183 / 183 |
lung | 100% | 4270.96 | 578 / 578 | 100% | 16.48 | 1155 / 1155 |
bladder | 100% | 4504.90 | 21 / 21 | 99% | 15.57 | 501 / 504 |
breast | 100% | 4073.25 | 459 / 459 | 99% | 17.79 | 1111 / 1118 |
brain | 99% | 2983.96 | 2619 / 2642 | 100% | 17.02 | 705 / 705 |
intestine | 100% | 3923.78 | 966 / 966 | 99% | 12.56 | 522 / 527 |
thymus | 100% | 4442.19 | 653 / 653 | 99% | 16.60 | 599 / 605 |
prostate | 100% | 4045.14 | 245 / 245 | 99% | 14.23 | 497 / 502 |
pancreas | 100% | 3316.23 | 328 / 328 | 99% | 14.91 | 176 / 178 |
ovary | 100% | 4858.33 | 180 / 180 | 98% | 10.44 | 422 / 430 |
uterus | 100% | 4873.21 | 170 / 170 | 98% | 14.69 | 450 / 459 |
kidney | 100% | 2599.89 | 89 / 89 | 98% | 13.45 | 879 / 901 |
stomach | 100% | 3341.96 | 359 / 359 | 98% | 12.72 | 279 / 286 |
adrenal gland | 100% | 3184.49 | 258 / 258 | 97% | 11.81 | 224 / 230 |
skin | 100% | 3464.12 | 1809 / 1809 | 91% | 12.35 | 431 / 472 |
liver | 100% | 2553.36 | 226 / 226 | 90% | 7.78 | 365 / 406 |
adipose | 100% | 3842.50 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3369.52 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 4477.92 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 12.71 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.49 | 1 / 1 |
muscle | 100% | 1945.31 | 800 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2182.83 | 850 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 9.55 | 25 / 29 |
peripheral blood | 73% | 1727.53 | 681 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 69% | 6.92 | 55 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0007519 | Biological process | skeletal muscle tissue development |
GO_0032786 | Biological process | positive regulation of DNA-templated transcription, elongation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0019085 | Biological process | early viral transcription |
GO_0051301 | Biological process | cell division |
GO_0019086 | Biological process | late viral transcription |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0008024 | Cellular component | cyclin/CDK positive transcription elongation factor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0070063 | Molecular function | RNA polymerase binding |
GO_0061575 | Molecular function | cyclin-dependent protein serine/threonine kinase activator activity |
GO_0003682 | Molecular function | chromatin binding |
GO_0001223 | Molecular function | transcription coactivator binding |
GO_0097322 | Molecular function | 7SK snRNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CCNT2 |
Protein name | Cyclin T2 Cyclin-T2 (CycT2) |
Synonyms | |
Description | FUNCTION: Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin T) complex, also called positive transcription elongation factor B (P-TEFB), which is proposed to facilitate the transition from abortive to production elongation by phosphorylating the CTD (carboxy-terminal domain) of the large subunit of RNA polymerase II (RNAP II) . The activity of this complex is regulated by binding with 7SK snRNA . Plays a role during muscle differentiation; P-TEFB complex interacts with MYOD1; this tripartite complex promotes the transcriptional activity of MYOD1 through its CDK9-mediated phosphorylation and binds the chromatin of promoters and enhancers of muscle-specific genes; this event correlates with hyperphosphorylation of the CTD domain of RNA pol II (By similarity). In addition, enhances MYOD1-dependent transcription through interaction with PKN1 . Involved in early embryo development (By similarity). .; FUNCTION: (Microbial infection) Promotes transcriptional activation of early and late herpes simplex virus 1/HHV-1 promoters. . |
Accessions | ENST00000446247.5 ENST00000264157.10 [O60583-1] F2Z2C9 ENST00000452839.5 H7BZ27 ENST00000438691.1 H7C411 C9JUL2 ENST00000295238.11 [O60583-2] O60583 F8WDY7 ENST00000417175.1 ENST00000452521.1 ENST00000419781.5 |